SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences completes $166 million Assertio acquisition

17 Jun 2026 Evaluate

Zydus Lifesciences has completed acquisition of Assertio Holdings Inc. (Assertio) for a total consideration of $166.33 million. The acquisition has been executed through Zara Merger Sub Inc. (Zara), a step down wholly owned acquisition subsidiary of the company. Post this acquisition, Zara has been merged with and into Assertio. Further, Assertio has become a wholly owned subsidiary of the company. The common stocks of Assertio are no longer listed or traded on the Nasdaq Global Market.

Assertio is a U.S. based specialty oncology pharmaceutical company with established commercial capability of marketing and distribution of differentiated oncology products. Assertio’s product ROLVEDON (eflapegrastim-xnst) is approved as Biologics License Application (BLA) by USFDA for long-acting G-CSF biologic for the prevention of febrile neutropenia in adult cancer parents receiving myelosuppressive chemotherapy. ROLVEDON is administered once per chemotherapy cycle in the oncology supportive care market. Assertio is headquartered in Lake Forest, Illinois.

Zydus Lifesciences (formerly known as Cadila Healthcare) operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

1141.00 41.35 (3.76%)
03-Jul-2026 16:01 View Price Chart
Peers
Company Name CMP
Sun Pharma. Inds. 1904.65
Dr. Reddys Labs. 1374.55
Cipla 1458.45
Zydus Lifesciences 1141.00
Lupin 2476.10
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through: